Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest

dc.creatorGirard, P. M.
dc.creatorCampbell, T. B.
dc.creatorGrinsztejn, Beatriz
dc.creatorHartikainen, J.
dc.creatorRachline, A.
dc.creatorNijs, S.
dc.creatorWitek, J.
dc.date.accessioned2018-11-12T17:58:03Z
dc.date.accessioned2023-09-05T15:39:22Z
dc.date.available2018-11-12T17:58:03Z
dc.date.available2023-09-05T15:39:22Z
dc.date.created2018-11-12T17:58:03Z
dc.date.issued2012
dc.identifierGIRARD, P. M. et al. Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest. HIV Medicine, v. 13, n. 7, p. 427-435, 2012.
dc.identifier1464-2662
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/30004
dc.identifier10.1111/j.1468-1293.2012.00994.x
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8668864
dc.languageeng
dc.rightsrestricted access
dc.titlePooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest
dc.typeArticle


Este ítem pertenece a la siguiente institución